VFMCRP announces U.S. Court upholds validity of Velphoro® patent
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251 which covers the formulation for Velphoro® (sucroferric oxyhydroxide). The decision, subject to appeal, holds that the generic sucroferric oxyhydroxide product proposed by Teva Pharmaceuticals USA, Inc., in its Abbreviated New Drug Application (ANDA) will infringe the Velphoro® U.S. patent no. 9,561,251, which expires in July 2030 (including pediatric extension). Currently, Velphoro® is protected by multiple Orange Book listed patents which expire between May 2029 and May 2035.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220821005007/en/
A further ANDA patent infringement lawsuit against Teva based on patents no. 10,682,376, no. 10,695,367 and no 11,013,761, all expiring in May 2029 remains pending.
“CSL Vifor welcomes the decision by the U.S. District Court to uphold the patent validity of Velphoro® which highlights the innovation and strength of our intellectual property,” said Florian Jehle, Chief Executive Officer of VFMCRP. “We are vigorously defending our intellectual property and protecting our market position. With this decision, we can continue to deliver this innovative drug to improve the lives of patients with chronic kidney disease on dialysis.”
VFMCRP has previously settled disputes with Lupin Pharmaceuticals, Inc and Annora Pharma Pvt. Ltd. which had filed ANDAs to market a generic version of Velphoro®. These ANDA filers will be able to launch a generic version of Velphoro® in the United States on an agreed-upon date. Details of all settlements are confidential.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
About Velphoro®
Velphoro® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis. Velphoro® has been launched in 32 countries at the end of 2021, with more than 100,000 patients estimated to use the drug on a yearly basis.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220821005007/en/
Contact information
CSL Vifor Media Contact
Thomas Hutter
Mobile: +41 79 957 96 73
Email: media@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Technology Reply Optimizes Pusterla 1880’s Quotation Management with Oracle AI Capabilities, Reducing the Estimation Time by 90%29.4.2025 11:00:00 EEST | Press release
Technology Reply, the Reply Group company specialising in designing solutions based on Oracle technologies, today announced the development of an AI-based solution for managing the quotation process at Pusterla 1880. The implementation has reduced the time required to create new quotations to under five minutes and decreased the time needed to generate and validate cost estimates by 90%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429596543/en/ “Leveraging the AI capabilities offered by Oracle Cloud Infrastructure and Oracle Database 23ai, and supported by Technology Reply’s expertise, we have significantly streamlined our quotation process. This has enabled us to respond more quickly to customer requests while reducing the risk of errors in our decision-making,” said Luca Meana, President, Pusterla 1880. Pusterla 1880, a company with over 140 years of experience in luxury packaging production, faced increasing complex
CSG and NetLync Drive MNO and MVNO eSIM Transformation29.4.2025 10:30:00 EEST | Press release
With eSIM set to become the standard for all new phones this year,mobile network operators (MNOs) and mobile virtual network operators (MVNOs) face mounting pressure to modernize their entitlement infrastructure. To address this market need, CSG® (NASDAQ: CSGS) today announced a new partnership with leading entitlement server provider NetLync and launched CSG Entitlements-as-a-Service, powered by NetLync. This new SaaS platform gives operators the speed and agility they need to power seamless iOS and Android experiences in weeks, not months. It helps them stay competitive in an eSIM-only future and avoid the high costs of building and managing their own entitlement infrastructure. “The shift to eSIM-only devices drives a major change in the telecommunications industry that will redefine user experiences,” said Chad Dunavant, Chief Product & Strategy Officer, CSG. “This evolution creates an exciting opportunity for early movers to spark disruption and unlock powerful new revenue streams
Suzano 2024 Annual Report on Form 20-F29.4.2025 10:29:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2024 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20250429838200/en/
SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital29.4.2025 10:29:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the “Vivo group”) against the legitimate and lawful actions of the Board. Dear Shareholders, We are writing to set the record straight in response to the Vivo group’s recent press releases, lawsuits and other actions against SINOVAC and the Board, particularly those related to the Board’s decision to declare a cash dividend of US$55.00 per common share to SINOVAC shareholders. The Vivo group is now attempting to block the special dividend payments to you via lawsuits and by sending threatening letters and messages to the Company’s stock transfer agent and board members. It is particularly concerning that the Vivo group is trying to prevent all SINOVAC common shareholders (who hav
KRAFTON Achieves Record-High Quarterly Sales in Q1 202529.4.2025 10:00:00 EEST | Press release
KRAFTON, Inc. today announced its first quarter earnings results for 2025. Based on consolidated financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS), the company achieved a record-high quarterly sales performance of 874.2B KRW and operating profit of 457.3B KRW. In addition to high quarter-over-quarter growth, year-over-year growth has also set records with sales up by 31.3% and operating profit upby 47.3%. Significant Growth and Core IP Direction KRAFTON achieved significant growth across all of its business divisions, including PC (323.5B KRW), mobile (532.4B KRW), and console/others (18.3B KRW). On PC platforms, PUBG: BATTLEGROUNDS’ diversified content and strong live-service operations contributed significantly to growth while the successful launch of a new IP, inZOI, also played a pivotal role. On mobile, premium items, strategic IP collaborations, and localized marketing efforts drove increased sales. This was especially tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom